Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 34 of 1,261
  1. US 12336974

    Methods and compositions for preventing and treating auditory dysfunctions

    United States Government as represented by the Department of Veterans Affairs · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  2. US 12338219

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  3. US 12338459

    DNA-chimeric antigen receptor T cells for immunotherapy

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  4. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  5. US 12338218

    Crystal form of benzimidazole-2-one compound, solvate thereof, crystal form of solvate thereof, and preparation method thereof

    Medshine Discovery Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  6. US 12338231

    N-heterocycle substituted tryptamine derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  7. US 12338242

    TYK2 inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  8. US 12338199

    Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  9. US 12336990

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  10. US 12338249

    Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  11. US 12338274

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  12. US 12338437

    OPA1 antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  13. US 12338450

    Gene therapy constructs for treating Wilson disease

    Ultragenyx Pharmaceutical Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  14. US 12338438

    Conjugated oligonucleotide compounds, methods of making and uses thereof

    E-Therapeutics PLC · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  15. US 12337017

    Microbiota transfer therapy for Pitt Hopkins Syndrome

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  16. US 12337199

    Stable antibody formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  17. US 12338439

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  18. WO 2025125508

    COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ

    CASSIOPEA S P A [IT] · Granted Jun 19, 2025 · Expires Jun 14, 2045

    granted
  19. IT 202300027246

    Matrici farmaceutiche per il rilascio prolungato di farmaci

    ANGELINI PHARMA S P A [IT] · Granted Jun 19, 2025 · Expires Jun 14, 2045

    granted
  20. WO 2025126115

    DÉGRADATION DE L'IRAK4 PAR CONJUGAISON D'INHIBITEURS D'IRAK4 AVEC DES LIGANDS DE LIGASE E3 ET PROCÉDÉS D'UTILISATION

    BEIGENE SWITZERLAND GMBH [CH] · Granted Jun 19, 2025 · Expires Jun 14, 2045

    granted
  21. US 2025195525

    ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Jun 19, 2025 · Expires Jun 14, 2045

    granted
  22. US 12331105

    Broadly neutralizing antibodies against HIV

    United States Government as represented by the Department of Veterans Affairs · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  23. US 12331124

    ALK2 antibodies and methods of use thereof

    Keros Therapeutics, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  24. US 12331110

    Monoclonal antibodies against endotrophin and the use thereof

    The Board of Regents of the University of Texas System · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.